SCYNEXIS
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SCYNEXIS and other ETFs, options, and stocks.About SCYX
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.
CEODavid Angulo Gonzalez
CEODavid Angulo Gonzalez
Employees28
Employees28
HeadquartersJersey City, New Jersey
HeadquartersJersey City, New Jersey
Founded1999
Founded1999
Employees28
Employees28
SCYX Key Statistics
Market cap26.98M
Market cap26.98M
Price-Earnings ratio-1.21
Price-Earnings ratio-1.21
Dividend yield—
Dividend yield—
Average volume242.64K
Average volume242.64K
High today$0.67
High today$0.67
Low today$0.6376
Low today$0.6376
Open price$0.653
Open price$0.653
Volume182.41K
Volume182.41K
52 Week high$1.31
52 Week high$1.31
52 Week low$0.565
52 Week low$0.565
Stock Snapshot
As of today, SCYNEXIS(SCYX) shares are valued at $0.64. The company's market cap stands at 26.98M, with a P/E ratio of -1.21.
On 2026-01-20, SCYNEXIS(SCYX) stock moved within a range of $0.64 to $0.67. With shares now at $0.64, the stock is trading +0.8% above its intraday low and -4.1% below the session's peak.
Trading activity shows a volume of 182.41K, compared to an average daily volume of 242.64K.
The stock's 52-week range extends from a low of $0.57 to a high of $1.31.
The stock's 52-week range extends from a low of $0.57 to a high of $1.31.
People also own
Based on the portfolios of people who own SCYX. This list is generated using Robinhood data, and it’s not a recommendation.